Molecular target
5-HT1F Receptor
Serotonin receptor on trigeminal nerve terminals — agonism reduces pro-inflammatory neuropeptide release implicated in migraine pathophysiology. Selective 5-HT1F agonism (lasmiditan / Reyvow) avoids the 5-HT1B-mediated vasoconstriction of triptans, expanding the population eligible for acute migraine therapy (e.g., patients with cardiovascular contraindications to triptans).
Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.
No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.
Pharmaceutical agents
Drugs that act on 5-HT1F Receptor
These medications have 5-HT1F Receptor among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.